bioMerieux Enters Agreement With GSK

Published: 17-Nov-2009

To develop predictive test for selective breast cancer patients

bioMerieux has entered into an agreement with GlaxoSmithKline (GSK) to develop a predictive test to help clinicians select the most appropriate treatment for different segments of breast cancer patients. This test is based on emerging biomarkers and will be intended for use in both adjuvant and metastatic breast cancer settings, subject to regulatory approvals.

Reportedly, the development of the new test will be co-funded by both companies. GSK, will bring its extensive experience in the field of cancer and conducting clinical studies and will also facilitate access to samples from several clinical trials under the collaboration.

In addition, the new test will be developed by bioMerieux's global R&D team, including its subsidiary, bioTheranostics. The company said that following clinical evaluation, the test will be launched by bioTheranostics in its CLIA-certified laboratory, after which an in-vitro diagnostic kit will be developed by bioMerieux and introduced to the global market leveraging the resources of bioMerieux and the collaboration.

Stephane Bancel, CEO bioMerieux, said: "This new collaboration is a significant milestone in our theranostics strategy. Working with GSK, we hope to achieve an important breakthrough in breast cancer care, helping oncologists to determine the most appropriate treatment as early as possible to give a significant number of breast cancer patients the chance for a better outcome."

Tell your friend about this article